FN2 Earnings Intelligence

Biogen Inc. analyst ratings

Biogen Inc. (BIIB) analyst consensus, price targets, and firm-level rating history from FN2 Research.

Analyst Consensus ?

ConsensusBuy49 ratings
Bullish3163.3%
Neutral1734.7%
Bearish12.0%

Analyst 52W Price Targets

$217.15Current
$157Low
$250.52Average
$415High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 13, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
HSBC Reduce ReduceMaintainSep 10, 2026
Piper Sandler Overweight OverweightMaintainSep 3, 2026
RBC Capital Outperform OutperformMaintainAug 25, 2026
Wolfe Research Outperform Peer PerformUpgradeAug 13, 2026
Mizuho Outperform OutperformMaintainAug 4, 2026
Citigroup Neutral NeutralMaintainAug 3, 2026
Wedbush Neutral NeutralMaintainJul 30, 2026
UBS Buy BuyMaintainJul 30, 2026
Show 41 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $217.15. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Stifel NicolausPaul Matteis$242$214.77 +11.4%Sep 10, 2026
HSBCAnalyst unavailable$175$210.73 -19.4%Sep 10, 2026
Piper SandlerAnalyst unavailable$245$222.67 +12.8%Sep 3, 2026
RBC CapitalAnalyst unavailable$260$218.12 +19.7%Aug 25, 2026
Wolfe ResearchAnalyst unavailable$300$208.87 +38.2%Aug 13, 2026
Morgan StanleyTerence Flynn$231$206.5 +6.4%Jul 30, 2026
H.C. WainwrightAnalyst unavailable$251$205.74 +15.6%Jul 30, 2026
RBC CapitalAnalyst unavailable$240$204.1 +10.5%Jul 30, 2026
UBSAnalyst unavailable$240$204.62 +10.5%Jul 30, 2026
Canaccord GenuityAnalyst unavailable$248$209.23 +14.2%Jul 30, 2026
See 131 more

Track every rating change on BIIB the moment it posts. Free to start.

Start free